Audrey Duval Derveloy, currently president of Sanofi France, has been named executive vice president, global head of corporate affairs.
Ms Duval Derveloy will also become a member of French pharma major Sanofi’s (Euronext: SAN) executive committee, reporting into chief executive Paul Hudson, and will be based in Paris. Her appointment is effective July 1, 2024.
In her new role, Ms Duval Derveloy will be responsible for Sanofi’s stakeholder engagement globally, and oversee the company’s corporate social responsibility strategy, not-for-profit Global Health Unit and Sanofi’s philanthropic arm, Foundation S. She retains her role as president, Sanofi France, and will continue supporting and coordinating Sanofi’s representation to its various external stakeholders in this country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze